The recent strategic partnership Siemens Healthineers AG recently entered into with Boston Scientific Corp. to develop and commercialize an Acunav 4D intracardiac echocardiography catheter could drive “significant growth” for the company, Jochen Schmitz, CFO, at Siemens, told delegates at the Jefferies Global Healthcare Conference, in London.
The limited efficacy of cancer immunotherapy is usually attributed to suboptimal antitumor T-cell generation, as well as impaired immunological memory development. MDX-2004 is a trispecific antibody-fusion protein developed by Modex Therapeutics Inc. that targets CD3, CD28 and CD137 on human T cells, which was designed to overcome these limitations by rejuvenating the immune system and enhancing antitumor immunity.
At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers from Circle Pharma Inc. presented their recent work on developing novel compounds that specifically target cyclin D1 while avoiding the toxicity associated with targeting cyclin D3.
Researchers from Chantibody Therapeutics Inc. presented the preclinical characterization of CT-111, a trispecific antibody engineered to simultaneously target PD-1, CTLA-4, and VEGF.
Arginase 1 (Arg1) is a key mediator of immune suppression, and its overexpression has been reported in multiple cancers, including renal cell carcinoma, pancreatic cancer, and head and neck cancer. However, clinical strategies aimed at inhibiting Arg1 function have achieved only limited success.
At the 2025 annual meeting of the Society for Neuroscience in San Diego this week, Catherine Woolley’s plenary lecture was an unusual combination of debunking and affirming the importance of sex differences in the brain.
The health care sector continues to be strong and adaptable despite the challenges over the past year, according to a report by global investment bank Jefferies. High interest rates, geopolitical uncertainty and policy shifts have added caution to the industry, but leaders are adapting well.
Although tricomplex pan-RAS (ON) inhibitors, such as RMC-6236, constitute a promising class of therapeutics against RAS-driven cancers, their on-target, off-tumor toxicities challenge the dosing strategy and the safety of drug combinations.
Inactivation of the tumor suppressor p53 occurs in approximately half of human cancer cases. In particular, the Y220C point mutation, which induces p53 misfolding and inactivation, is found in about 1% of solid tumors. Previous research identified a unique, druggable pocket on the p53 surface created by this mutation that constitutes a promising cancer therapeutic target.
In glioblastoma multiforme, MTAP loss leads to MTA accumulation, which partially inhibits PRMT5, making the cells reliant on residual PRMT5 activity for survival. Targeting this remaining PRMT5 with MTA-cooperative inhibitors induces synthetic lethality, representing a promising targeted approach for MTAP-deleted gliomas. Researchers from Ryvu Therapeutics SA reported the preclinical profile of RVU-305, a PRMT5 inhibitor, in MTAP-deleted cancer models.
RSS
